Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Grows By 6.6%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a significant growth in short interest in August. As of August 31st, there was short interest totalling 25,800 shares, a growth of 6.6% from the August 15th total of 24,200 shares. Based on an average trading volume of 56,000 shares, the short-interest ratio is presently 0.5 days.

Global X Genomics & Biotechnology ETF Stock Down 0.8 %

Shares of NASDAQ GNOM opened at $11.35 on Thursday. The firm has a market cap of $84.44 million, a P/E ratio of -4.87 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a twelve month low of $8.63 and a twelve month high of $12.53. The company has a 50 day moving average of $11.27 and a 200 day moving average of $10.89.

Institutional Trading of Global X Genomics & Biotechnology ETF

Institutional investors and hedge funds have recently modified their holdings of the business. James J. Burns & Company LLC boosted its position in shares of Global X Genomics & Biotechnology ETF by 35.6% during the fourth quarter. James J. Burns & Company LLC now owns 18,479 shares of the company’s stock valued at $214,000 after buying an additional 4,848 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Global X Genomics & Biotechnology ETF by 16.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 377,749 shares of the company’s stock worth $4,431,000 after acquiring an additional 53,178 shares during the period. Centaurus Financial Inc. grew its stake in shares of Global X Genomics & Biotechnology ETF by 14.6% in the fourth quarter. Centaurus Financial Inc. now owns 12,738 shares of the company’s stock worth $147,000 after acquiring an additional 1,624 shares during the period. One Capital Management LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 22.1% during the second quarter. One Capital Management LLC now owns 680,311 shares of the company’s stock valued at $7,102,000 after purchasing an additional 123,339 shares during the last quarter. Finally, Insight Advisors LLC PA boosted its holdings in Global X Genomics & Biotechnology ETF by 59.0% in the second quarter. Insight Advisors LLC PA now owns 21,177 shares of the company’s stock worth $221,000 after purchasing an additional 7,861 shares during the last quarter. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.